Novel Death Defying Domain in met entraps the active site of caspase-3 and blocks apoptosis in hepatocytes

Hepatology

Volumn 59, Issue 5, 2014, Pages 2010-2021

  Ma, Jihong ^a   Zou, Chunbin ^a   Guo, Lida ^a   Seneviratne, Danushka S ^a   Tan, Xinping ^a   Kwon, Yong Kook ^a   An, Jiyan ^b   Bowser, Robert ^b   Defrances, Marie C ^a   Zarnegar, Reza ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; BINDING SITES; CASPASE 3; CASPASE INHIBITORS; CYTOPROTECTION; HEPATOCYTES; HUMANS; MICE; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-MET;

EID: 84899478673     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26769     Document Type: Article

References (22)

1. Corso S, Comoglio PM, Giordano S. Cancer therapy: can the challenge be MET? Trends Mol Med 2005;11:284-292.
2. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012;12:89-103.
3. Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010:11:834-848.
4. Zarnegar R, Michalopoulos GK. The many faces of hepatocyte growth factor: from hepatopoiesis to hematopoiesis. J Cell Biol 1995;129:1177-1180.
5. Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 1999;68:383-424.
6. Fuentes-Prior P, Salvesen GS. The protein structures that shape caspase activity, specificity, activation and inhibition. Biochem J 2004;384:201-232.
7. Cotter TG. Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer 2009;9:501-507.
8. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-674.
9. Yoshimori A, Sakai J, Sunaga S, Kobayashi T, Takahashi S, Okita N, et al. Structural and functional definition of the specificity of a novel caspase-3 inhibitor, Ac-DNLD-CHO. BMC Pharmacol 2007;7:8.
10. Dobo J, Swanson R, Salvesen GS, Olson ST, Gettins PG. Cytokine response modifier a inhibition of initiator caspases results in covalent complex formation and dissociation of the caspase tetramer. J Biol Chem 2006;281:38781-38790.
11. Riedl SJ, Renatus M, Snipas SJ, Salvesen GS. Mechanism-based inactivation of caspases by the apoptotic suppressor p35. Biochemistry 2001;40:13274-13280.
12. Stennicke HR, Renatus M, Meldal M, Salvesen, GS. Internally quenched fluorescent peptide substrates disclose the subsite preferences of human caspases 1, 3, 6, 7 and 8. Biochem J 2000;350:563-568.
13. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-7279.
14. Hoglen NC, Hirakawa BP, Fisher CD, Weeks S, Srinivasan A, Wong AM, et al. Characterization of the caspase inhibitor IDN-1965 in a model of apoptosis-associated liver injury. J Pharmacol Exp Ther 2001;297:811-818.
15. Rodriguez I, Matsuura K, Ody C, Nagata S, Vassalli P. Systemic injection of a tripeptide inhibits the intracellular activation of CPP32-like proteases in vivo and fully protects mice against Fas-mediated fulminant liver destruction and death. J Exp Med 1996;184:2067-2072.
16. Mehlen P, Puisieux, A. Metastasis: a question of life or death. Nat Rev Cancer 2006;6:449-458.
17. Rzychon M, Chmiel D, Stec-Niemczyk J. Modes of inhibition of cysteine proteases. Acta Biochim Pol 2004;51:861-873.
18. Foveau B, Leroy C, Ancot F, Deheuninck J, Ji Z, Fafeur V, et al. Amplification of apoptosis through sequential caspase cleavage of the MET tyrosine kinase receptor. Cell Death Differ 2007;14:752-764.
19. Seol D-W, Chan Q, Zarnegar R. Transcriptional activation of the hepatocyte growth factor receptor (c-met) gene by its ligand (hepatocyte growth factor) is mediated through AP-1. Oncogene 2000;24:1132-1137.
20. Dai JY, DeFrances MC, Zou C, Johnson CJ, Zarnegar, R. The Met protooncogene is a transcriptional target of NF kappaB: implications for cell survival. J Cell Biochem 2009;107:1222-1236.
21. Wang X, DeFrances MC, Dai Y, Pediaditakis P, Johnson C, Bell A, et al. A mechanism of cell survival: sequestration of Fas by the HGF receptor Met. Mol Cell 2002;9:411-421.
22. Zou C, Ma J, Wang X, Guo L, Zhu Z, Stoops J, et al. Lack of Fas antagonism by Met in human fatty liver disease. Nat Med 2007;13:1078-1085.